ENDRA Life Sciences (NDRA) Tops Q4 EPS by 1c
Get Alerts NDRA Hot Sheet
Join SI Premium – FREE
ENDRA Life Sciences (NASDAQ: NDRA) reported Q4 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08).
Cash and cash equivalents were $9.5 million as of December 31, 2021.
For earnings history and earnings-related data on ENDRA Life Sciences (NDRA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Some Said Inflation Risks Had Become More Skewed To Upside - FOMC Minutes
- Stifel Reiterates Buy Rating on Sportradar Group AG (SRAD) Amid 2% Drop
- Constellation Brands (STZ) PT Lowered to $155 at Goldman Sachs
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share